PIPA: Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.

Sponsor
Zealand University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04803422
Collaborator
(none)
2,631
2
2
32
1315.5
41.1

Study Details

Study Description

Brief Summary

The PIPA trial is a prospective, multicentre, cluster randomized cluster crossover non-inferiority study. We aim to test whether a three-day postoperative course of per oral antibiotics is non-inferior to a three-day postoperative course of intravenous antibiotics as standard care after laparoscopic surgery for complicated appendicitis in regards to the risk of postoperative intraabdominal abscess formation within 30-days

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Complicated appendicitis increases the risk of postoperative intra-abdominal abscess. Treatment of complicated appendicitis are usually with a postoperative course of intravenous antibiotics. There is need for a study confirming the results of retrospective studies showing that a postoperative course of oral antibiotics is not inferior to intravenous antibiotics after laparoscopic surgery for complicated appendicitis.

The PIPA trial will be a prospective, multicenter, cluster randomized cluster crossover non-inferiority study designed to test whether a three-day postoperative course of per oral antibiotics is non-inferior to a three-day postoperative course of intravenous antibiotics as standard care after laparoscopic surgery for complicated appendicitis in regards to the risk of postoperative intraabdominal abscess formation within 30-days. Participating hospitals will be randomized to either a 6-month period with a per oral antibiotic regime followed by a 6-month period with an intravenous antibiotic regime, or 6-month period with an intravenous antibiotic regime followed by a 6-month period with a per oral antibiotic regime for the postoperative treatment after laparoscopic surgery for complicated appendicitis. Primary outcome will be the incidence of intra-abdominal abscess by the postoperative day 30.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2631 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Masking Description:
An electronic randomization sequence in the program R will be applied to randomize centers (clusters) 1:1. After randomization the allocation will not be concealed
Primary Purpose:
Treatment
Official Title:
Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis: A Cluster Randomized Cluster Crossover Non-Inferiority Study.
Actual Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Arm 1- Postoperative Course

Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim. First 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin. Last 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim.

Drug: Antibiotic
The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
Other Names:
  • metronidazole intravenous
  • metronidazole oral
  • Piperacillin / Tazobactam
  • Amoxicillin / Clavulanic acid
  • Active Comparator: Arm 2 - Postoperative Course

    Pre-or intraoperative antibiotics (both uncomplicated and complicated) appendicits: Single-dose inj. Metronidazole and Pipperacillin/Tazobactam. In case of allergy to penicillin: Single-dose inj. Metronidazole and intravenous inj. Cefuroxim. First 6 month: Intravenous Metronidazole and Intravenous Pipperacillin / Tazobactam. In case of allergy to penicillin: Intravenous Metronidazole and Intravenous Cefuroxim. Last 6 month: Tablet Amoxicillin/Clavulanic Acid and Tablet Metronidazole.In case of allergy to Penicillin: Tablet Metronidazole and Tablet Ciprofloxacillin.

    Drug: Antibiotic
    The study aims to test whether oral antibiotics is non-inferior compared to intravenous antibiotics.
    Other Names:
  • metronidazole intravenous
  • metronidazole oral
  • Piperacillin / Tazobactam
  • Amoxicillin / Clavulanic acid
  • Outcome Measures

    Primary Outcome Measures

    1. Intra-abdominal abscess [Assessed at postoperative day 30]

      Primary outcome is defined as an imaging verified intraabdominal mass treated with drainage or antibiotics, or a surgically verified intra-abdominal abscess

    Secondary Outcome Measures

    1. postoperative stay [The event is assessed at postoperative day 30. The event is determnied beginning from the time the surgery ends till the time the patient is discharged from the hospital.]

      postoperative length of stay measured in hours

    2. Complications according to Clavien-Dindo Classifcation [Assessed at postoperative day 30]

      complications according to the Clavien-Dindo classification at postoperative day 30, that require in- or outpatient treatment, complications grade ≥3a according to Clavien-Dindo Classification at postoperative day 30

    3. Costs [Assessed at postoperative day 30. Data for both in- and outpatient costs will be extracted from the Danish Health Authority]

      In- and outpatient costs and overall costs of both in-and- outpatient

    4. Wound infection [Assessed postoperative day 30]

      Postoperative wound infection that require in-and - outpatient treatment. A wound infection is defined as a clinically suspected wound infection which has been treated with an opening of the wound or where antibiotics has been administered for this indication

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • On cluster level, hospitals with emergency surgical admissions performing laparoscopic appendectomies are eligible for inclusion.

    • On an individual level, participants are eligible for inclusion if they undergo a laparoscopic appendectomy for appendicitis (both uncomplicated and complicated), are ≥ 18 years of age, and provide a signed written consent form.

    Exclusion Criteria:
    • Exclusion criteria are specifically related to the therapy and individual participants will be excluded if they undergo any other procedures than laparoscopic appendectomy during index surgery.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Slagelse Hospital, Department of Surgery Slagelse Denmark 4200
    2 Department of Surgery, Slagelse Hospital Slagelse Denmark

    Sponsors and Collaborators

    • Zealand University Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zealand University Hospital
    ClinicalTrials.gov Identifier:
    NCT04803422
    Other Study ID Numbers:
    • P-2021-27
    First Posted:
    Mar 17, 2021
    Last Update Posted:
    Jul 14, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 14, 2022